Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses

To learn more about Organicell, download the latest research report here

Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a pioneer in the Extracellular Vesicle (EV) space. They have already been developing exosome-based drug candidates for the treatment and prevention of COVID-19, Long COVID, Chronic Obstructive Pulmonary Disease (COPD), osteoarthritis, and other conditions. Its flagship product, Zofin™, is in human clinical trials. Since being FDA approved for an expanded access trial, the company has also treated 18 people with the exosome-based therapy and the results are promising with patients showing reduced inflammation and improved lung function.

New Information Linking Exosomes and the Common Cold

However, a possible new reason for companies like Organicell to get excited about EVs has recently been uncovered by researchers at Harvard University.

“In what researchers are calling a scientific breakthrough, scientists behind a new study may have found the biological reason we get more respiratory illnesses in winter. It turns out the cold air itself damages the immune response occurring in the nose.”

It seems that EVs have an absolutely crucial role in preventing germs from effectively entering and getting a foothold in the body through the nose. The body creates and uses EVs to mop up and get rid of harmful agents, but this becomes seemingly far more difficult when the temperature outside gets extra low.

“In fact, that little bit of coldness in the tip of the nose was enough to take nearly 42% of the extracellular vesicles out of the fight…”

One of the researchers, Dr. Benjamin Bleier, “expects to see the development of topical nasal medications that build upon this scientific revelation. These new pharmaceuticals will ‘essentially fool the nose into thinking it has just seen a virus,’ he said.”

The Emerging Research On Exosomes Is Filled With Promise, But Still New

While often confused with stem cells, exosomes are not cells. They are the smallest of all Extracellular Vesicles (EVs) – the various particles cells secrete to send messages and materials to each other. EVs are how cells tell each other to reproduce, differentiate into specific cells, repair, and so on. It’s also how cells pass along proteins, lipids, DNA, RNA, and other materials that the receiving cell might need to carry out those functions.

EVs may have the potential to reduce inflammation, repair damaged tissue, and otherwise help cells regenerate and heal.

Their ability to carry cargo to a cell has also attracted interest from biopharmaceutical developers who are looking into using EVs as a delivery mechanism for therapeutics. If these developers can engineer EVs that carry a specific drug to specific cells – like delivering chemotherapeutic agents to tumor cells – they could create more targeted treatments with fewer adverse reactions. Biotech companies are working on creating the technology necessary to reliably engineer exosomes to create potent and highly targeted treatments.

This field of study is still emerging and there is a lot that researchers still don’t yet know about EVs. A lot of the most promising data to come out about these messenger particles is from animal and cell culture studies. So a major hurdle the research still needs to overcome is whether those exciting findings will translate to human studies.

Organicell is among the companies to have already begun human trials for an exosome therapy. ZofinTM, its lead drug candidate, is being developed as a potential treatment for COVID, Long COVID, COPD, and osteoarthritis.

Does all this mean even bigger opportunities for treatments and products for companies like Organicell?

Learn more about Organicell’s research and products here.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent.

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties.

Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (

You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Organicell Investor Relations

Company Website

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.